Dolutegravir and Rilpivirine
- Generic Name
- Dolutegravir and Rilpivirine
- Indication
用于治疗接受稳定的抗逆转录病毒治疗方案达到病毒学抑制（HIV-1 RNA小于50拷贝/mL）至少六个月，无病毒学失败史，且对非核苷类逆转录酶抑制剂或整合酶抑制剂没有已知或疑似耐药性的成人人类免疫缺陷病毒1型（HIV-1）感染患者。
Pharmacokinetics of JULUCA in Hemodialysis
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 8
- Registration Number
- NCT04431518
- Locations
- 🇺🇸
Samir Gupta, Indianapolis, Indiana, United States
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 16
- Registration Number
- NCT03984838
- Locations
- 🇺🇸
GSK Investigational Site, Glendale, California, United States
Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 209
- Registration Number
- NCT03518060
- Locations
- 🇩🇪
GSK Investigational Site, Weimar, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath